Diéguez-Campa C, Pérez-Neri I

Language: Spanish
References: 14
Page: 73-77
PDF size: 180.85 Kb.

ABSTRACT

The importance of looking backwards regarding Parkinson disease (PD) lies in understanding its early description and classification to direct us towards its treatment. Documents from 4,000 years ago include clinical signs of the disease, in 1817 James Parkinson described it as a neurological disorder called “paralysis agitans”; Martin Charcot completed the syndrome description, identifying bradikinesia, different types of tremor, non-motor symptoms and the term “Parkinson disease” was employed. Brissaud proposed that damage in the substantia nigra was the underlying pathology of PD. From the elucidation of its pathophysiology and the development of experimental models mimicking some characteristics of the disease, it has been possible to establish some therapeutic strategies. Several models exist which show both advantages and disadvantages, like 6-hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. MTPT was discovered by serendipity in intravenous drug users. Even though no model replicates the whole disease, due to its high reproducibility, the presence of both motor and non-motor symptoms as well as Lewy bodies, and mainly, because of its selectivity for damaging the substantia nigra, the use of MTPT in monkeys is considered the gold standard; thus, a fortunate finding becomes a valuable experimental tool.

REFERENCES

1. 1.García S, López B, Meza EG, Villagómez AJ, Vázquez RC. Breve reseña histórica de la enfermedad de Parkinson. De la descripción precipitada de la enfermedad en el siglo XIX, a los avances en Biología Molecular del padecimiento. Med int Mex 2010; 26(4): 350-73.

2. 2.Parkinson J. An essay on the shaking palsy. Whittingham and rowland for sherwood, Needly and Jones 1817.

3. 3.Charcot JM. Leçons sur les maladies du systeme nerveux 1872.

4. 4.Gowers WR. A manual of diseases of the nervous system 1888.

5. 5.Brissaud E. Leçons sur les maladies nerveuses1925.

6. 6.Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003; 39: 889-909.

7. 7.Tieu K. A Guide to neurotoxic animal models of parkinson's disease. Cold spring harb perspect med 2011;1(1): a009316-a009316.

8. 8.Porter CC, Totaro JA, Burcin A. The relationchip between radioactivity and norepinephrine concentrations in the brains and hearts of mice following administration of labeled methyldopa or 6-hydroxydopamine. J Pharmacol Exp Ther 1965; 150:17-22.

9. 9.Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences betweem MPTP-induced parkinsonism and Parkinson’s disease: Neuropathologic considerations. Adv Neurol 1993; 60: 600-8.

10. 10.Fox SH, Brotchie JM. The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future. Prog Brain Res 2010; 184: 133-57.

11. 11.Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, et al. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and alpha synuclein. Proc Natl Acad Sci 2005;102:3413-18.

12. 12.Anderson G, Noorian AR, Taylor G, Annitha M, Bernhard D, Srinivasan S, et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Pakinson’s disease. Exp Neurol 2007; 207: 4-12.

13. 13.Bezard E, Przedborski S. Parkinson’s disease: animal models-primates Park. Mov Disord 2011; 26: 993-1002.

14. 14.Goetz CG. The history of parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 2011; 1: a008862